Compare Aptiv PLC (APTV) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aptiv PLC vs Pfizer Inc — how do they compare? Aptiv PLC trades at $60.08 (market cap $12.82B), while Pfizer Inc trades at $24.24 (market cap $137.76B). The key difference: Pfizer Inc is far larger — about 10.7× Aptiv PLC's market cap, and Pfizer Inc pays a 7.12% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | PFE | |
|---|---|---|
Market Cap | $12.82B | $137.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $28.56 |
52-Week Low | $52.57 | $23.29 |
Enterprise Value | $19.53B | $188.41B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
Pfizer (PFE) trades at $24.17, down 0.33% on the day, with a bearish technical signal and neutral oscillators. The company maintains solid fundamentals with a P/E of 18.45, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline developments in obesity and oncology, with a $0.43 quarterly dividend providing income stability.
The outlook remains mixed: analyst consensus targets $27.63 (14% upside) but technicals suggest near-term pressure. Key risks include patent cliffs and competitive threats, while institutional sentiment leans hold. Valuation appears reasonable relative to cash flow generation, making PFE a defensive play with moderate growth potential amid ongoing pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
